SC EOC wants to add a new system to help students be career-ready by graduation
COLUMBIA, S.C. (WSPA) – This week in Columbia, the Education Oversight Committee (EOC) voted on a major update to South Carolina's education system; it's what they call the 'South Carolina Tiered Credential System.' This new initiative is designed to make students more career-ready by the time they graduate, giving them the skills and required credentials to step straight into the workforce.
Basically, it's a free certificate system that is meant to ensure employers that students are prepared and ready for the workforce.
'They'll be able to really hit the ground running, as we like to say. They'll be ready to go and ready to work in these industries in South Carolina,' said Tenell Felder, who runs Communications for the EOC.
The system is broken down into three tiers:
Covers basic, industry-specific skills
Includes credentials that boost employability
Features credentials required for high-wage and high-demand careers
'It's just a nice start that gives you a heads up over other people that might be applying for a job…. If you're needing to work your way through college, it's great to have this because you're going to be able to get into a higher wage job and help pay your way through college if that's what you want to,' said Senator Ross Turner (R – Greenville).
Turner, who is a member of the EOC, and Felder agree that this program would also be great for students who do not know exactly what they want to do yet.
'That might give you the opportunity to explore a little bit, to decide, especially with the tiered system, you know, you're not going straight into the, the certifications that you need for a specific industry. You can kind of explore a little bit,' Felder added
They say it can also help students learn essential life skills.
'Being explained to you that you got to show up on time, you got to work hard, you've got to be participating, and there's going to be change, and you've got to accept change. Those kinds of skills are going to be good. Whatever they end up doing, even if they don't want to get into something industry specific,' said Turner.
Turner said The State Department of Education, Department of Employment and Workforce, and the Southern Regional Education Board have worked with the Education Oversight Committee to develop this system.
The Committee is expected to meet again in June. If the updated system is officially approved, it will go into effect in August.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 hours ago
- Yahoo
Charles Barkley's Parting ‘Inside the NBA' Message
Charles Barkley's Parting 'Inside the NBA' Message originally appeared on Athlon Sports. NBA on TNT's iconic run has come to an end. This is after the Indiana Pacers defeated the New York Knicks, 125-108, in Game 6 of the Eastern Conference finals on Saturday night. Advertisement The East finals were TNT's last NBA broadcast as their TV rights deal comes to an end at the conclusion of the 2024-25 season. This only means that Saturday night was TNT's final "Inside the NBA" show. Hall of Famer Charles Barkley is a member of the long-running program's legendary quartet, and the 62-year-old could not help but get emotional in his final farewell message. "Obviously, I got lucky and made one of the best decisions ever," Barkley started. "I was obviously going to go to NBC, and a friend of mine, Michael Jackson, says, 'Come to have dinner at Turner. It'll make me look good.' "And these guys took me out to dinner, and after five hours, I had to call the great Dick Ebersol and say, 'Hey, man, I'm going to change my mind.'" Advertisement Barkley then went on to show his appreciation to everyone and anyone he has encountered during his two and a half decades with TNT. "I just want to thank every single person who's been at Turner with me the last 25 years. 25 years," he said. "... So if you're with people that long, they are your family. And I just want to thank everybody at Turner for the last 25 years. "It's been an honor, and I'm grateful and thankful." NBA legend Charles Barkley at the 2024 NBA Finals at American Airlines Jairaj-Imagn Images Barkley will be taking his talents to ESPN as "Inside the NBA" transfers to the renowned sports network starting next season. The former NBA MVP also had a few things to say to ESPN ahead of his much-anticipated debut. Advertisement "And also to ESPN, it's going to be an honor and a privilege to work for you guys," he said. "You guys are the number one sports network in history. I'm excited for it. You guys got some tremendous talents over there. I'm looking forward to co-working with those guys." Barkley ended his emotional monologue by expressing how grateful he is for the life he's lived, and how much TNT has impacted the same. "But like I said, man, I just want to say thank you to the NBA, every coach I've had, every player I've played with for giving me this magnificent life that I've had," Barkley said. "I am so lucky and blessed. I'm lucky and blessed. Advertisement "And I want to thank TNT. And even though we'll never say TNT Sports again, I want to thank TNT for giving me a magnificent life." As they always say, all good things must come to an end. Related: Charles Barkley Issues Serious Warning to Pacers on Saturday This story was originally reported by Athlon Sports on Jun 1, 2025, where it first appeared.
Yahoo
19 hours ago
- Yahoo
AstraZeneca drug could help keep a common breast cancer at bay
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Too often, cancer has a way of evading treatment. Tumors that were held in check begin to spread anew, forcing doctors to try different drugs in a desperate race to keep malignant cells from multiplying. For a common type of breast cancer, this usually happens because of changes in a gene called ESR1. Mutations there can drive cancer growth even as physicians' first choice of therapy chokes off the resources that tumors had relied on to survive. Afterwards, the prognosis for patients gets worse. Multiple second-line medicines exist, but 'their benefit is limited, quality of life decreases and survival rates are low,' according to Nicholas Turner, director of clinical research and development at the Royal Marsden Hospital in London. New study results from Turner and others show an experimental drug from AstraZeneca, camizestrant, can help sustain the benefit of first-line therapy. Unveiled Sunday, their research found that, once ESR1 mutations are detected, swapping out a standard component of that initial regimen for AstraZeneca's drug reduced the risk of disease progression or death by more than half. Data from the study, which AstraZeneca funded and in February said succeeded, will be presented Sunday afternoon at the American Society of Clinical Oncology's annual meeting. 'Patients have an urgent need for new treatments that can prolong time on first-line therapy and delay disease progression,' Turner said in a statement provided by ASCO. In their clinical trial, Turner and colleagues enrolled 3,256 people with advanced breast cancer positive for hormone receptors but negative for a protein called HER2. These individuals are typically treated with a kind of hormone therapy known as an aromatase inhibitor along with another type of targeted drug that interrupts cancer cell division. Participants in the study were monitored via blood tests for the emergence of ESR1 mutations, which were eventually detected in about 550 people. Three-hundred and fifteen were then randomly assigned to receive camizestrant instead of the aromatase inhibitor or to continue on with their initial regimen. These patients continued to receive those targeted drugs, 'CDK 4/6 inhibitors.' Patients who were switched to camizestrant had a 56% lower risk of their cancer progressing or killing them than those who continued on, researchers calculated. Put another way, people in the camizestrant group lived a median of 16 months without disease progression or death, compared to 9.2 months for those in the control arm. Data also showed camizestrant helped maintain quality of life for longer than did aromatase inhibitors, too. Researchers continue to follow study participants to measure differences between the groups in overall survival, but don't yet have enough follow-up data to determine whether there is a benefit on that score. Less than 2% of patients in either group discontinued treatment due to side effects, which, for camizestrant, were consistent with what AstraZeneca has observed in prior testing. Hormone receptor-positive, HER2-negative tumors are the most common type of breast cancer, accounting for an estimated 70% of cases. Hormone receptors provide a dock for estrogen, which spurs the tumor to grow. In first-line therapy, hormone therapy shuts off estrogen signaling by either gumming up hormone receptors on the surface of breast cancer cells, or by blocking the body from making estrogen. But about 40% of patients whose breast cancer is responsive to hormone therapy develop ESR1 mutations during their initial therapy, according to an estimate cited by ASCO. Research done a decade ago at Memorial Sloan Kettering Cancer Center discovered that ESR1 mutations change the shape of the estrogen receptor, essentially flipping it 'on,' whether or not cancer cells continue to receive an estrogen growth signal. Camizestrant offers a way to get ahead of that change by breaking down the estrogen receptor entirely. It's one of a new crop of so-called selective estrogen receptor degraders, or SERDs, that are taken orally rather than injected like the drug fulvestrant, which has been a staple of breast cancer treatment for decades. One member of this fresh class, Orserdu, won U.S. approval in 2023. Others from Eli Lilly and Roche, as well as a different kind of degrader from partners Pfizer and Arvinas, are in late-stage testing. Data from a Phase 3 trial involving Pfizer and Arvinas' vepdegestrant in people whose hormone receptor-positive, HER2-negative breast cancer progressed following initial treatment were presented at ASCO Saturday. The setting envisioned by camizestrant's trial is one step earlier, subbing in a SERD before initial disease progression to allow patients to remain on first-line therapy longer. 'When patients progress on scans, we're already behind. We've already lost control, in some sense,' Eleonora Teplinsky, head of breast and gynecologic medical oncology at New Jersey's Valley-Mount Sinai Comprehensive Cancer Care, said in a press conference held by ASCO. 'An early switch approach, before we see disease progression on imaging, [allows] us to stay ahead of the curve.' Switching early requires regular monitoring, which Turner and his colleagues accomplished by using 'liquid biopsies,' tests that pick up fragments of tumor DNA circulating in the blood. While these are relatively expensive, Turner said he hopes insurance would cover them should camizestrant win approval in the tested setting. Clearance would also change doctors' testing practice. Soon after Orserdu won U.S. approval, ASCO updated its treatment guidelines to recommend testing for ESR1 mutations following disease progression or recurrence. Camizestrant's benefit lies in delaying that progression, making active surveillance beforehand essential. 'The difference here is this serial monitoring for evidence of the evolving mutation,' said Julie Gralow, an oncologist and ASCO's chief medical officer, at the press conference. Establishing reimbursement and updating guidelines will be important to that goal, acknowledged Mohit Manrao, a senior vice president in AstraZeneca's U.S. oncology division. 'The good part here is that the test exists,' he added 'It is already being done at the point of progression,' he said. AstraZeneca plans to use the data presented at ASCO to request regulatory approval. It is also studying replacing aromatase inhibitors with camizestrant upfront, rather than waiting for ESR1 mutations to emerge. Two other trials are examining camizestrant's potential in early breast cancer.
Yahoo
2 days ago
- Yahoo
ASU Commercial Aviation Program introduces helicopter pilot degree track
SAN ANGELO, Texas (Concho Valley Homepage) —Angelo State Universities Commercial Aviation Program is reaching new heights. Starting this fall semester, the Commercial Aviation Program will offer a helicopter pilot degree track. Scott Turner is the program director. ''Commercial aviation flight operations helicopter and aviation air traffic control operations so obviously for helicopter people who want to become pilots for EMS law enforcement or something like that and then for air traffic operations…people who want to be air traffic controllers and that sort of thing,' Turner said. With the addition of this degree track, Turner said ASU is now one of the few universities nationwide to offer a degree for both helicopter and fixed wing pilots. Even fewer universities offer air traffic control and aviation administration. He says this new degree track is being offered to help meet a growing industry demand. 'There is always a need for that type of service-based pilot career path. It just kind of fit naturally with what we are already teaching,' Turner said. One aspect of this program is the importance of hands-on training for the students. ''We want them to be able to fly as soon as possible I mean if you are coming in to get a degree and you want to fly an aircraft you don't want to wait two years before you do it ,so we don't do things like get a bunch of core classes knocked out before you get to do the thing that you want to do…we recognize that as a need of the student,' Turner said. Currently the Commercial Aviation Program has about 175 students with applications still open for the remaining seats in the program. Turner said they hope to add around 100 more students. 'We still have some seats available, so I would encourage people if that is what they are wanting to do and look at that as a career apply to ASU as soon as you can let's get admitted let's get accepted into the program and let's go fly,' Turner said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
